Quantum Technology Partners

Magnolia Broadband, Inc. is a fabless semiconductor company based in Englewood, New Jersey, specializing in wireless communications. Founded in 2000, the company has developed and patented Mobile Transmit Diversity (MTD), a beam-forming technology that enhances data throughput and coverage for wireless network operators without requiring changes to existing base stations or infrastructure. Magnolia's technology can be deployed as either a chip or a software solution, offering significant advantages such as a 40% increase in spectrum utilization and improved performance for voice and data services. The company holds a substantial intellectual property portfolio, including 28 issued patents and 24 pending patents in the United States, along with additional patents in various international markets. Magnolia’s MTD technology supports multi-band standards and protocols, enabling rapid, cost-effective deployment while extending battery life and reducing emissions.

Vaxart, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on the discovery and development of oral recombinant protein vaccines utilizing its proprietary oral vaccine platform. The company’s product pipeline features a norovirus vaccine, which has completed Phase I clinical trials, and an oral tablet vaccine targeting the GI.1 and GII.4 norovirus strains. Additionally, Vaxart is advancing a seasonal influenza vaccine currently in Phase II trials for H1 influenza, as well as vaccines for respiratory syncytial virus and coronavirus. The company is also engaged in developing therapeutic immune-oncology vaccines aimed at cervical cancer and dysplasia linked to human papillomavirus. Furthermore, Vaxart has a research collaboration with Janssen Vaccines & Prevention B.V. to explore its oral vaccine platform in the context of a universal influenza vaccine program. Founded in 2004, Vaxart is dedicated to creating innovative vaccine solutions to combat infectious diseases.

BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors. BiPar has raised around $60 million in VC funding, from firms like [Domain Associates](/financial-organization/domain-associates), [Canaan Partners](/financial-organization/canaan-partners-3), [Vulcan Capital](/financial-organization/vulcan-capital), [PolyTechnos Venture Partners](/financial-organization/polytechnos-venture-partners), [Asset Management Company](/financial-organization/asset-management), and [Quantum Technology Partners](/financial-organization/quantum-technology-partners). It also has raised venture debt from [Lighthouse Capital Partners](/financial-organization/lighthouse-capital-partners). On April 15th, 2009, French drug maker [Sanofi-Aventis S.A.](/organization/sanofi-aventis-2) announced it was acquiring BiPar Sciences for up to $500 million.

Vaxart, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on the discovery and development of oral recombinant protein vaccines utilizing its proprietary oral vaccine platform. The company’s product pipeline features a norovirus vaccine, which has completed Phase I clinical trials, and an oral tablet vaccine targeting the GI.1 and GII.4 norovirus strains. Additionally, Vaxart is advancing a seasonal influenza vaccine currently in Phase II trials for H1 influenza, as well as vaccines for respiratory syncytial virus and coronavirus. The company is also engaged in developing therapeutic immune-oncology vaccines aimed at cervical cancer and dysplasia linked to human papillomavirus. Furthermore, Vaxart has a research collaboration with Janssen Vaccines & Prevention B.V. to explore its oral vaccine platform in the context of a universal influenza vaccine program. Founded in 2004, Vaxart is dedicated to creating innovative vaccine solutions to combat infectious diseases.

Corium International, Inc. is a biopharmaceutical company specializing in the development, manufacture, and commercialization of specialty pharmaceutical products that utilize transdermal and transmucosal delivery systems. The company offers several products, including a clonidine transdermal delivery system for hypertension, fentanyl patches for chronic pain management, and Crest Whitestrips for teeth whitening. Its product pipeline features innovative therapies, such as Twirla, a hormonal contraceptive patch, and a transdermal system for severe osteoporosis. Additionally, Corium is developing transdermal systems for Alzheimer's disease, psychiatric disorders, and motion sickness. The company collaborates with various pharmaceutical partners to advance its product offerings. Established in 1995, Corium International is headquartered in Menlo Park, California, and operates with a focus on enhancing therapeutic outcomes through advanced drug delivery technologies.

StrataGent Life Sciences, Inc. is a specialty drug therapy company developing painless, non-invasive versions of therapies that would otherwise be injected. Its products are based on its proprietary microjet technology, which delivers large and small therapeutic molecules without a device penetrating into or through the skin. In May of 2004, StrataGent received a $2 million award from the Advanced Technology Program (ATP) at the National Institute of Standards and Technology to support the development of the StrataGent microjet technology.

BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors. BiPar has raised around $60 million in VC funding, from firms like [Domain Associates](/financial-organization/domain-associates), [Canaan Partners](/financial-organization/canaan-partners-3), [Vulcan Capital](/financial-organization/vulcan-capital), [PolyTechnos Venture Partners](/financial-organization/polytechnos-venture-partners), [Asset Management Company](/financial-organization/asset-management), and [Quantum Technology Partners](/financial-organization/quantum-technology-partners). It also has raised venture debt from [Lighthouse Capital Partners](/financial-organization/lighthouse-capital-partners). On April 15th, 2009, French drug maker [Sanofi-Aventis S.A.](/organization/sanofi-aventis-2) announced it was acquiring BiPar Sciences for up to $500 million.

IMI Intelligent Medical Implants develops and markets intelligent retinal implant systems for degenerative retinal disorders. The company offers The Intelligent Retinal Implant System, an adaptive visual prosthesis that bridges and replaces the defective information processing function of the real retina in patients with retinal degeneration. IMI Intelligent Medical Implants was founded in 2002 and is based in Zug, Switzerland.

Magnolia Broadband, Inc. is a fabless semiconductor company based in Englewood, New Jersey, specializing in wireless communications. Founded in 2000, the company has developed and patented Mobile Transmit Diversity (MTD), a beam-forming technology that enhances data throughput and coverage for wireless network operators without requiring changes to existing base stations or infrastructure. Magnolia's technology can be deployed as either a chip or a software solution, offering significant advantages such as a 40% increase in spectrum utilization and improved performance for voice and data services. The company holds a substantial intellectual property portfolio, including 28 issued patents and 24 pending patents in the United States, along with additional patents in various international markets. Magnolia’s MTD technology supports multi-band standards and protocols, enabling rapid, cost-effective deployment while extending battery life and reducing emissions.

BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors. BiPar has raised around $60 million in VC funding, from firms like [Domain Associates](/financial-organization/domain-associates), [Canaan Partners](/financial-organization/canaan-partners-3), [Vulcan Capital](/financial-organization/vulcan-capital), [PolyTechnos Venture Partners](/financial-organization/polytechnos-venture-partners), [Asset Management Company](/financial-organization/asset-management), and [Quantum Technology Partners](/financial-organization/quantum-technology-partners). It also has raised venture debt from [Lighthouse Capital Partners](/financial-organization/lighthouse-capital-partners). On April 15th, 2009, French drug maker [Sanofi-Aventis S.A.](/organization/sanofi-aventis-2) announced it was acquiring BiPar Sciences for up to $500 million.

Southampton Photonics Ltd., a U.K. startup. The company, with origins at Southampton University's Optical Research Center (ORC), aims to establish itself in the design and manufacture of fiber-optic components for the dense wave-division multiplexing (DWDM) and optical telecommunications market using technology from the university.

Southampton Photonics Ltd., a U.K. startup. The company, with origins at Southampton University's Optical Research Center (ORC), aims to establish itself in the design and manufacture of fiber-optic components for the dense wave-division multiplexing (DWDM) and optical telecommunications market using technology from the university.